真实世界的参芎葡萄糖注射液治疗缺血性脑血管病临床联合用药特征分析

发布时间：2018-11-12 11:38

【摘要】：为了分析真实世界的参芎葡萄糖注射液治疗缺血性脑血管病的临床用药特征。提取全国19家三甲医院信息系统(HIS)数据库中使用参芎葡萄糖注射液治疗缺血性脑血管病的患者的基本信息、中西医诊断信息、医嘱信息、实验室检查信息,采用Apriori算法建立模型,使用Clementine 12.0进行关联分析,分析真实世界中参芎葡萄糖注射液临床用药特征。结果符合纳入标准的784例患者的联合用药中,共包含411种西药和110种中药。联合用药频次最高的单个西药是阿司匹林515例(65.69%),单个中药是银杏叶提取物121例(15.43%),2种西药是阿托伐他汀+阿司匹林(关联规则度为10.15%),3种西药是阿托伐他汀+氯吡格雷+阿司匹林(关联支持度为5.56%),常与抗生素类、活血化瘀剂药物联合应用。结果表明,参芎葡萄糖注射液在治疗缺血性脑血管病时临床上常与抗血小板药和活血化瘀药联合应用,有助于增强抗血小板聚集和活血化瘀作用,应注意药物联合应用时的配伍禁忌,保证临床用药安全性的前提下联合用药达到药效增强的作用。
[Abstract]:To analyze the clinical characteristics of Shenxiong glucose injection in the treatment of ischemic cerebrovascular diseases in the real world. To extract the basic information of patients with ischemic cerebrovascular disease treated with Shenxiong glucose injection in the (HIS) database of information system of 19 third-class hospitals in China, the information of diagnosis of traditional Chinese and western medicine, the information of doctors' orders, the information of laboratory examination, Apriori algorithm was used to establish the model and Clementine 12.0 was used to analyze the clinical characteristics of Shenxiong glucose injection in real world. Results there were 411 kinds of western medicine and 110 kinds of traditional Chinese medicine in 784 patients. Aspirin 515 cases (65.69%), ginkgo biloba extract 121 cases (15.43%) and Atto vastatin aspirin (10.15%). The three kinds of western medicine were Atto vastatin clopidogrel aspirin (associated support was 5.56%), which was often used in combination with antibiotics and blood circulation drugs. The results showed that Shenxiong glucose injection in the treatment of ischemic cerebrovascular disease is often combined with antiplatelet drugs and blood circulation drugs, which is helpful to enhance the effect of anti-platelet aggregation and promoting blood circulation and removing blood stasis. We should pay attention to the incompatibility contraindication of combined use of drugs to ensure the safety of clinical use of drugs to achieve the effect of enhancing the efficacy.
【作者单位】：中国中医科学院中医临床基础医学研究所;中国人民大学统计学院;中国人民解放军海军总医院;
【基金】：国家“重大新药创制”科技重大专项(2015ZX09501004-001-002) 北京市中医药科技发展专项(JJ2014-53) 国家中医药管理局中医药行业科研项目(201507003)
【分类号】：R277.7

【相似文献】